SUZHOU and SHANGHAI China, Dec 15, 2023 - Forlong Biotechnology, a clinical stage biotech dedicated to developing next-generation cytokine therapeutics, today announced that the first patient was dosed in its Phase I clinical trial evaluating FL115（i.v.）monotherapy, a next-generation IL-15 super agonist. FL115 is presently undergoing a Phase I clinical trial in the United States (NCT06130722) for the treatment of advanced, locally unresectable or metastatic solid tumours; the first subject was dosed on 12 December 2023, U.S. time.

About FL115

FL115 is a next-generation, long-acting IL-15/IL-15Rα monomeric Fc-fusion protein wholly developed by Forlong Biotech via Fbody platform. Its unique single-arm structure delivers antibody-like yields, enhanced tumor penetration, and an exemplary safety profile. Pre-clinical studies demonstrate FL115 has significantly wider therapeutic index than comparator IL-15 agents, enabling efficacious dosing at markedly higher exposure levels.

About Forlong Biotechnology

Forlong Biotechnology is a clinical stage biotechnology company dedicated to developing next-generation cytokine therapeutics.Focusing on tumor immunology, Forlong develops engineering therapeutic cytokine combinations that act at distinct steps of the cancer–immunity cycle to treat cancer. The leading asset, FL115, is a clinical stage super agonist of interleukin-15 (IL-15) that can activate natural killer (NK) cells and memory T cells. Pre-clinical studies demonstrate FL115 has significantly wider therapeutic index than comparator IL-15 agents, enabling efficacious dosing at markedly higher exposure levels.